To include your compound in the COVID-19 Resource Center, submit it here.

C.R. Bard, Lutonix deal

Bard acquired Lutonix for $225 million in cash plus

Read the full 96 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE